←Back to Expert Scholars
Translational Medicine / 转化医学CLL BTK Resistance Research
John Byrd
MD
🏢University of Cincinnati🌐USA
Professor of Medicine
120
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
John Byrd is a pioneer of BTK inhibitor therapy who led the clinical development of ibrutinib that revolutionized CLL treatment. His research on BTK inhibitor resistance mutations, particularly C481S, has defined the field. He continues to develop strategies to overcome covalent BTK inhibitor resistance through novel agents and combinations.
Share:
🧪Research Fields 研究领域
Ibrutinib development
BTK biology
CLL clinical trials
Kinase inhibitor resistance
B-cell malignancy therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 John Byrd 的研究动态
Follow John Byrd's research updates
留下邮箱，当我们发布与 John Byrd（University of Cincinnati）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment